Exciting Developments in Vitiligo Treatment by China Medical System
SHENZHEN, CHINA – China Medical System Holdings Limited, along with its subsidiaries referred to as the Group or CMS, is excited to announce a significant advancement in dermatological care. The National Medical Products Administration of China (NMPA) has accepted the New Drug Application (NDA) for ruxolitinib phosphate cream, which is specifically designed for treating vitiligo. This momentous approval not only opens doors for this innovative cream in the Chinese market but also brings hope to millions of individuals living with vitiligo.
Positive Results from Ruxolitinib Cream Trials
A recent Real-World Study conducted in China revealed the effectiveness of ruxolitinib cream. By the 24-week mark, nearly half of the patients using this cream showed a F-VASI 75 response, which exceeded expectations. These results underscore the cream's potential to reduce lesions and encourage skin repigmentation for patients suffering from non-segmental vitiligo. Importantly, the treatment maintained a favorable safety profile with minimal adverse effects, allowing patients to continue their therapy without significant interruptions or serious complications.
Production Strategy Focused on Localization
As the NDA process continues, CMS is actively improving the localization of ruxolitinib cream's production. The transition from international manufacturing to local production is underway, facilitated by a Contract Development Manufacturing Outsourcing Organization (CDMO). Initial lab-scale and pilot studies are complete, and large-scale production will begin soon, ensuring that Chinese patients have timely access to this treatment.
Understanding Vitiligo: An Ongoing Challenge
Vitiligo is an autoimmune disorder that results in skin depigmentation due to the loss of melanocytes, the cells responsible for skin pigmentation. In China, around 14 million people live with vitiligo, with the non-segmental variant being the most common. Current treatments like topical corticosteroids and calcineurin inhibitors often fall short, highlighting a significant gap in effective therapies for these patients. Should it receive approval, ruxolitinib cream would offer a groundbreaking prescription option for those battling vitiligo.
Commitment to Innovation and Improvement
CMS is dedicated to addressing unmet medical needs by delivering innovative and competitive solutions. The company has been enhancing its research and development capabilities, both through internal efforts and strategic collaborations, to expand its portfolio of potential products. Going forward, CMS will actively seek global innovations that can efficiently be introduced to the Chinese market, ensuring that patients receive the highest quality treatments available.
What is Ruxolitinib Cream?
Ruxolitinib cream, or Opzelura, is a topical formulation of a selective JAK1/JAK2 inhibitor that the FDA has approved in the United States for treating non-segmental vitiligo in individuals aged 12 and older. It is noteworthy for being the first treatment specifically aimed at skin repigmentation for vitiligo in the U.S. Additionally, it has received support for treating atopic dermatitis when conventional therapies do not succeed.
Improving Access to the Market
Although ruxolitinib cream is not yet approved by the NMPA for general use, it was granted Urgent Clinical Import approval by the Hainan Medical Products Administration. This made it available for patients in the Hainan Boao Lecheng International Medical Tourism Pilot Zone shortly after, demonstrating a strong commitment to providing timely access to new therapies for those who need them.
Collaboration with Incyte to Expand Reach
In December, CMS's dermatology-focused subsidiary entered into a key collaboration and licensing agreement with Incyte, which enables CMS to develop, register, and commercialize ruxolitinib for various dermatological conditions in regions including Mainland China and Southeast Asia. This partnership highlights CMS's strong pipeline and commitment to addressing autoimmune and inflammatory skin diseases.
Aiming for Greater Impact
The collaboration with Incyte places CMS in a strong position, allowing for the introduction of advanced treatments not only in China but also in nearby markets. By expanding into Southeast Asia as well, CMS aims to bridge the gap between global pharmaceutical innovations and local market needs.
Frequently Asked Questions
What does the NDA acceptance mean?
The NDA acceptance is a crucial step toward making ruxolitinib cream accessible to vitiligo patients in China, providing them with a new treatment option.
How effective is ruxolitinib cream for vitiligo?
Clinical studies have shown that nearly 50% of patients treated with ruxolitinib cream experienced a significant degree of skin repigmentation.
Are there safety concerns with ruxolitinib cream?
Reported adverse events during clinical trials were mostly mild to moderate, with no serious side effects causing treatment discontinuation.
What does the localization strategy mean for production?
The localization strategy focuses on moving production from overseas sites to domestic manufacturing, enhancing the accessibility and availability of the product within China.
What role does CMS play in this process?
CMS is responsible for the development, registration, and commercialization of ruxolitinib cream in China, ensuring its swift and efficient market entry.
